Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/CAAC.21763

Article  PubMed  Google Scholar 

Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63–89. https://doi.org/10.14740/WJON1191

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen K, Kostos L, Azad AA (2022) Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer. World J Urol. https://doi.org/10.1007/S00345-022-04135-8/TABLES/3

Article  PubMed  PubMed Central  Google Scholar 

Burdak-Rothkamm S, Mansour WY, Rothkamm K (2020) DNA damage repair deficiency in prostate cancer. Trends Cancer 6:974–984. https://doi.org/10.1016/j.trecan.2020.05.011

Article  CAS  PubMed  Google Scholar 

Zhang D, Xu X, Wei Y et al (2022) Prognostic role of DNA damage response genes mutations and their association with the sensitivity of olaparib in prostate cancer patients. Cancer Control 29:1–16. https://doi.org/10.1177/10732748221129451

Article  Google Scholar 

Schiewer MJ, Knudsen KE (2019) DNA damage response in prostate cancer. Cold Spring Harb Perspect Med. https://doi.org/10.1101/CSHPERSPECT.A030486

Article  PubMed  PubMed Central  Google Scholar 

Conteduca V, Mosca A, Brighi N et al (2021) New prognostic biomarkers in metastatic castration-resistant prostate cancer. Cells 10:1–13. https://doi.org/10.3390/CELLS10010193

Article  Google Scholar 

European Medicines Agency (2022) EMA recommends restricting use of cancer medicine Rubraca. https://www.ema.europa.eu/en/news/ema-recommends-restricting-use-cancer-medicine-rubraca. Accessed 24 July 2023

The European Medicines Agency - EMA (2022) Lynparza | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza. Accessed 24 July 2023

Anscher MS, Chang E, Gao X et al (2021) FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA-mutated metastatic castrate-resistant prostate cancer. Oncologist 26:139. https://doi.org/10.1002/ONCO.13585

Article  CAS  PubMed  Google Scholar 

FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer | FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lynparza-olaparib-abiraterone-and-prednisone-brca-mutated. Accessed 24 July 2023

Sternberg CN, Petrylak DP, Sartor O et al (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27:5431–5438. https://doi.org/10.1200/JCO.2008.20.1228

Article  CAS  PubMed  Google Scholar 

Ross RW, Beer TM, Jacobus S et al (2008) A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112:521–526. https://doi.org/10.1002/CNCR.23195

Article  CAS  PubMed  Google Scholar 

Hager S, Ackermann CJ, Joerger M et al (2016) Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 27:975–984. https://doi.org/10.1093/ANNONC/MDW156

Article  CAS  PubMed  Google Scholar 

Corn PG, Heath EI, Zurita A et al (2019) Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol 20:1432–1443. https://doi.org/10.1016/S1470-2045(19)30408-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu M, Mo QG, Wei CY et al (2013) Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis. Oncol Lett 5:983. https://doi.org/10.3892/OL.2012.1093

Article  CAS  PubMed  Google Scholar 

Yimit A, Adebali O, Sancar A (2019) Jiang Y (2019) Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs. Nat Commun 101(10):1–11. https://doi.org/10.1038/s41467-019-08290-2

Article  CAS  Google Scholar 

Zhang C, Xu C, Gao X, Yao Q (2022) Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 12:2115. https://doi.org/10.7150/THNO.69424

Article  PubMed  PubMed Central  Google Scholar 

Alderden RA, Hall MD, Hambley TW (2006) The discovery and development of cisplatin. J Chem Educ 83:728–734. https://doi.org/10.1021/ED083P728

Article  CAS  Google Scholar 

Hazlitt RA, Min J, Zuo J (2018) Progress in the development of preventative drugs for cisplatin-induced hearing loss. J Med Chem 61:5512–5524. https://doi.org/10.1021/ACS.JMEDCHEM.7B01653

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid S, Omlin A, Higano C et al (2020) Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations. JAMA Netw Open. https://doi.org/10.1001/JAMANETWORKOPEN.2020.21692

Article  PubMed  PubMed Central  Google Scholar 

Leal F, García-Perdomo HA (2019) Effectiveness of platinum-based chemotherapy in patients with metastatic prostate cancer: systematic review and meta-analysis. Clin Genitourin Cancer 17:e627–e644. https://doi.org/10.1016/J.CLGC.2019.03.008

Article  PubMed  Google Scholar 

Bouman-Wammes EW, van den Berg HP, de Munck L et al (2018) A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: the RECARDO trial. Eur J Cancer 90:1–9. https://doi.org/10.1016/J.EJCA.2017.11.021

Article  CAS  PubMed  Google Scholar 

de Wit R, de Bono J, Sternberg CN et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381:2506–2518. https://doi.org/10.1056/NEJMOA1911206/SUPPL_FILE/NEJMOA1911206_DATA-SHARING.PDF

Article  PubMed  Google Scholar 

Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability–an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11:220–228. https://doi.org/10.1038/NRM2858

Article  CAS  PubMed  Google Scholar 

Li X, Heyer WD (2008) Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 18:99. https://doi.org/10.1038/CR.2008.1

Article  CAS  PubMed  Google Scholar 

Stewart MD, Vega DM, Arend RC et al (2022) Homologous recombination deficiency: concepts, definitions, and assays. Oncologist 27:167. https://doi.org/10.1093/ONCOLO/OYAB053

Article  PubMed  PubMed Central  Google Scholar 

Mateo J, Boysen G, Barbieri CE et al (2017) DNA repair in prostate cancer: biology and clinical implications. Eur Urol 71:417–425. https://doi.org/10.1016/J.EURURO.2016.08.037

Article  CAS  PubMed  Google Scholar 

Catalano M, Generali D, Gatti M et al (2023) DNA repair deficiency as circulating biomarker in prostate cancer. Front. Oncol 13:1115241

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228. https://doi.org/10.1016/J.CELL.2015.05.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basourakos SP, Li L, Aparicio AM et al (2017) Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. Curr Med Chem 24:1586. https://doi.org/10.2174/0929867323666161214114948

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jia X, Wang K, Xu L et al (2022) A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer. Breast 66:31. https://doi.org/10.1016/J.BREAST.2022.08.012

Article  PubMed  PubMed Central  Google Scholar 

Stronach EA, Paul J, Timms KM et al (2018) Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy. Mol Cancer Res 16:1103–1111. https://doi.org/10.1158/1541-7786.MCR-18-0034

Article  CAS  PubMed  Google Scholar 

Costa IN, Reis J, Meireles S et al (2022) Metastatic castration-resistant prostate cancer with BRCA2 mutation: the challenge incorporating PARP inhibitors and platinum in treatment sequencing. Eur J Case Rep Intern Med. https://doi.org/10.12890/2022_003331

Article  PubMed  PubMed Central  Google Scholar 

Mota JM, Barnett E, Nauseef JT et al (2020) Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations. JCO Precis Oncol 4:355–366. https://doi.org/10.1200/PO.19.00346

Article  PubMed  Google Scholar 

Pomerantz MM, Spisák S, Jia L et al (2017) The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 123:3532–3539. https://doi.org/10.1002/CNCR.30808

Article  CAS  PubMed